Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Tirzepatide-based evidence from the SURPASS (Researching Tirzepatide in Patients with Type 2 Diabetes for Glycemic Control and Weight Management) trials (SURPASS-1 NCT03954834 and SURPASS-5 NCT04039503) demonstrated dose-dependent, significant weight loss over 40 weeks compared with placebo, along with reductions in BMI and waist circumference [62, 63]
Positive reviews consistently cite effective weight loss, responsive customer service, and competitive pricing
Nuestro Compromiso
Appetite Control Semaglutide influences appetite-related pathways, helping reduce hunger and food cravings
That suggests Zepbound's maximum dose is "stronger" than Wegovy's maximum dose, but it tells you nothing about how 1 mg of Wegovy compares to 5 mg of Zepbound
It is a consistent finding across every major trial program
US$ 21.97
US$ 21.28
US$ 20.33
US$ 20.60
